Unresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection.

Patients with resectable, locally advanced NSCLC (LA-NSCLC) have been historically recommended neoadjuvant chemotherapy (CT) followed by resection on the basis of randomized clinical trial data dating back to the 1980s.1,2 This standard of care recently changed after the publication of CheckMate 816, which revealed significant improvements in major pathologic response, pathologic complete response (pCR), and event-free survival when immune checkpoint inhibitors (ICIs) were combined with neoadjuvant CT (CT + ICI) for this population.